Brind.

UBS issued a sell recommendation on Oscar Health (OSCR) shares, citing market pressure and expected revenue slumps due to ACA/Obamacare.

1 report, 1 independent Updated Jul 18

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

UBS Oscar Health

Keep exploring

The entities involved

UBS
Swiss multinational investment bank and financial services company
- Multiple financial institutions, including Goldman Sachs, Morgan Stanley, Bank of America, UBS, and others, provided ratings and price targets for Marvell Technology on May 28, 2026.22:25
- SNB profit surpassed UBS forecasts while fears over the Iran war eased market risk.14:54
Oscar Health
U.S. health insurance company

Nothing else this week.

Coverage

Newest first; wire copies grouped

Jul 18Insider MonkeyOscar Health (OSCR) Falters on UBS’ “Sell” Reco We recently published These 10 Stocks Just Lost Their Spark. Oscar Health, Inc. (NYSE:OSCR) is one of the worst-performing companies on Thursday. Oscar